Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes
Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes
New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.
The SRFF team was led by Partner Jeffrey J. Fessler.
- Sichenzia Ross Ference LLP代表Laidlaw＆Company（UK）Ltd.完成Amesite Inc.的1,500万美元首次公开发行。 - September 30, 2020
- Sichenzia Ross Ference LLP代表Aegis Capital Corp.进行格林威治生命科学有限公司的725万美元首次公开发行。 - September 30, 2020
- Sichenzia Ross Ference合伙人Andrew M. J. Bernstein，Esq。向法律界颁发大陪审团CLE - September 20, 2020